Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

Effect of Preemptive Low Dose Norepinephrine Infusion on Intraoperative Hemodynamic Stability and Postoperative Outcomes in Patients Undergoing Brain Tumor Resection With a Craniotomy

Not Applicable

Not yet recruiting

Conditions: Brain Tumor

Interventions: Drug: norepinephrine

First Posted Date: 2023-04-18

Last Posted Date: 2023-04-18

Lead Sponsor: Yonsei University

Target Recruit Count: 70

Registration Number: NCT05814601

Locations: 🇰🇷
Yonsei University College of Medicine, Seoul, Korea, Republic of

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Phase 2

Recruiting

Conditions: Endometrial Cancer
Endometrial Neoplasms

Interventions: Drug: Nivolumab

First Posted Date: 2023-04-03

Last Posted Date: 2024-01-23

Lead Sponsor: Yonsei University

Target Recruit Count: 30

Registration Number: NCT05795244

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

The Effects of Sufentanil vs. Remifentanil in Total Intravenous Anesthesia With Remimazolam on Postoperative Pain

Not Applicable

Recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: sufentanil-remimazolam group
Drug: remifentanil-remimazolam group

First Posted Date: 2023-03-27

Last Posted Date: 2023-03-27

Lead Sponsor: Yonsei University

Target Recruit Count: 66

Registration Number: NCT05785234

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Lazertinib/Pemetrexed/Carboplatin

First Posted Date: 2023-03-27

Last Posted Date: 2023-03-27

Lead Sponsor: Yonsei University

Target Recruit Count: 87

Registration Number: NCT05786430

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial

Not Applicable

Recruiting

Conditions: Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation

Interventions: Drug: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
Drug: high-intensity statin monotherapy (atoravastatin 40mg)

First Posted Date: 2023-03-24

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 4310

Registration Number: NCT05782777

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Safety and Efficacy of Distal Radial Approach (SAFE-BOX)

Recruiting

Conditions: Efficacy
Safety

First Posted Date: 2023-03-20

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 3600

Registration Number: NCT05776550

Locations: 🇰🇷
Yongcheol Kim, Yongin, Gyeonggi-do, Korea, Republic of

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial

Not Applicable

Recruiting

Conditions: Synchronous Neoplasm
Kidney Cancer
Clear Cell Renal Cell Carcinoma Metastatic

Interventions: Procedure: Cytoreductive nephrectomy±metastasectomy
Other: Human-derived materials sampling

First Posted Date: 2023-03-03

Last Posted Date: 2023-06-22

Lead Sponsor: Yonsei University

Target Recruit Count: 40

Registration Number: NCT05753839

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Yongin Severance Hospital, Yongin-si, Korea, Republic of
🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

Phase 1

Not yet recruiting

Conditions: HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

Interventions: Drug: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Yonsei University

Target Recruit Count: 44

Registration Number: NCT05749900

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Portal Hypertension Using Magnetic Resonance Elastography

Completed

Conditions: Magnetic Resonance Imaging
Portal Hypertension

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Yonsei University

Target Recruit Count: 47

Registration Number: NCT05749198

Locations: 🇰🇷
Wonju Severance Christian Hospital, Wŏnju, Gangwon, Korea, Republic of

Effect of Mirabegron on Bladder Compliance

Not Applicable

Active, not recruiting

Conditions: Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics

Interventions: Drug: Mirabegron (beta3-adrenoceptor agonist), Anticholinergics

First Posted Date: 2023-02-27

Last Posted Date: 2023-02-27

Lead Sponsor: Yonsei University

Target Recruit Count: 15

Registration Number: NCT05745584

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy